Phase Two GI Phase two studies for ulcerative colitis and Crohn’s disease signal a need for specialized GI trial services, pharmacokinetic and pharmacodynamic support, and partnerships with IBD focused sites and CROs.

KOL Collaboration Recent additions to the clinical advisory board, including leading IBD physicians, indicate a readiness to engage in joint development, advisory collaborations, and data sharing with field leaders.

Targeted Delivery The prodrug is designed to activate in the terminal ileum and colon, creating opportunities to partner with GI research centers, biomarker programs, and regulatory strategies tailored to ileal and colonic disease endpoints.

Lean Operations With a small team and modest funding, Palisade could benefit from cost efficient outsourcing in clinical operations, regulatory affairs, medical writing, and trial execution to accelerate timelines.

Strategic Partnerships Active participation in industry events and board growth suggests openness to co development, licensing discussions, and strategic partnerships with larger pharma players seeking innovative therapies in inflammatory and fibrotic diseases.